BioSpace News Archive

TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that the Company will host a conference call and live audio webcast on Friday, September 17, 2021 at 9:00am E.T. to discuss extended data from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

Ocular Therapeutix, Inc. today reported in-market unit sales of DEXTENZA® billable inserts of 6,924 and 9,321 in July and August, respectively, as part of the Company’s corporate presentation at the H.C. Wainwright 23rd Annual Global Investment Conference

Plus Therapeutics, Inc. today announced the appointment of Norman LaFrance, M.D. to the position of Chief Medical Officer and Senior Vice President.

TELA Bio, Inc. today announced details of the clinical research presented last week at the Society of American Gastrointestinal and Endoscopic Surgeons (SAGES) meeting in Las Vegas, Nevada.

Thorne HealthTech, a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced the launch of its initial public offering.

aTyr Pharma, Inc. today announced positive results from its Phase 1b/2a double-blind, placebo-controlled clinical trial of its lead therapeutic candidate, ATYR1923

XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference held on September 13-15, 2021.

PolyPid Ltd. today announced positive preclinical data in two key Glioblastoma Multiform (GBM) animal models of its OncoPLEX intra-tumoral cancer therapy program.

Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes, today announced the appointment of Emma Reeve to its Board of Directors as Audit Committee Chair.

Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), today announced that management will host a shareholder update conference call on Monday, September 20, 2021, at 4:30 p.m. ET.